Accuray Incorporated has announced that studies continue to demonstrate the unmatched flexibility of the TomoTherapy System to treat, with precision and efficiency, a wide variety of indications of all complexities.
More than 50 studies were presented during poster and oral sessions at the 36th Annual European Society for Radiotherapy & Oncology (ESTRO) Meeting in Vienna, May 5-9.
Study highlights include:
"The data presented at the ESTRO 36 meeting continue to show that the benefits of the TomoTherapy System's ring gantry platform and daily 3D image guidance in the treatment of a range of clinical indications." said Fabienne Hirigoyenberry, VP Global Medical and Scientific Affairs of Accuray. "The Radixact System, the latest generation TomoTherapy platform, provides the same unrivaled delivery capabilities while giving clinicians the versatility to treat the broad spectrum of patients and disease types with the highest level of precision and increased speed and efficiency."Back To Top